- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Bliss GVS Pharma has announced a board meeting on the financial results for the quarter and year ended March 31, 2025, posting a strong consolidated net profit of ₹21.0 Cr. The Board has proposed a final dividend of 0.50 paisa per share (FV Rs.1), pending shareholder approval. Key moves include allotting up to 12.1 lakh sweat equity shares to top management for their contributions and planning the sale of a 51% stake in its Nigerian subsidiary for USD 1.3 million, targeting completion by September 2025.